ATHENA Sweeps 8 Criteria in Blind Tests Across 28 Rare Disease Groups
marinkazitnik · x · 2026-07-07
A research team invited domain experts from 28 rare disease organizations within the Biohub Rare As One network to conduct blind evaluations comparing ATHENA against reference models. The assessment covered various therapeutic cases, including neurodevelopmental disorders, epilepsy, metabolic diseases, and rare cancers. ATHENA outperformed baseline models across all 8 evaluation criteria, showing the most significant improvements in cognitive traceability and the helpfulness of its reasoning. Experts particularly praised its ability to provide evidence chain visualizations.
More from Research
- Krea 2 LoKr likeness guide says 750 steps is usually enough for near-perfect face training — LilBrownBebeShoes · 2026-07-22
- PoLar: Dynamically Skipping or Looping LLM Layers for Efficient Inference — ttkciar · 2026-07-22
- Stanford Team Introduces Gigatoken, the World's Fastest Tokenizer — StanfordAILab · 2026-07-22
- Tabul AI launches Metal TreeSHAP to speed up Shapley values on Apple silicon — Scobleizer · 2026-07-22
- ICML Tutorial: Is Optimization Theory Relevant in 2026? — srush_nlp · 2026-07-22
- Reddit points to OpenAI’s ChatGPT Ads page — EcstaticAsparagus509 · 2026-07-22